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Abstract
Background—In 2013–2014, an outbreak of serogroup B meningococcal disease occurred 
among persons linked to a New Jersey university (University A). In the absence of a licensed 
serogroup B meningococcal (MenB) vaccine in the US, the Food and Drug Administration 
authorized use of an investigational MenB vaccine to control the outbreak. An investigation of the 
outbreak and response was undertaken to determine the population at risk and assess vaccination 
coverage.
Methods—The epidemiologic investigation relied on compilation and review of case and 
population data, laboratory typing of meningococcal isolates, and unstructured interviews with 
university staff. Vaccination coverage data were collected during the vaccination campaign held 
under an expanded access Investigational New Drug protocol.
Results—Between March 25, 2013 and March 10, 2014, 9 cases of serogroup B meningococcal 
disease occurred in persons linked to University A. Laboratory typing results were identical for all 
8 isolates available. Through May 14, 2014, 89.1% coverage with the two-dose vaccination series 
was achieved in the target population. From the initiation of MenB vaccination through February 
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1, 2015, no additional cases of serogroup B meningococcal disease occurred in University A 
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students. However, the 9th case occurred in March 2014 in an unvaccinated close contact of 
University A students.
Conclusions—No serogroup B meningococcal disease cases occurred in persons who received 
1 or more doses of 4CMenB vaccine, suggesting 4CMenB may have protected vaccinated 
individuals from disease. However, the 9th case demonstrates that carriage of serogroup B 
Nesisseria meningitidis among vaccinated persons was not eliminated.
Keywords
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Introduction
Between March 25, 2013 and March 10, 2014, 9 cases of serogroup B meningococcal 
disease were reported in persons linked to a New Jersey university (University A). During 
this time, options for control of serogroup B meningococcal disease outbreaks were limited 
by the absence of a licensed serogroup B (MenB) vaccine in the US. However, in 2013 two 
recombinant MenB vaccines were under pre-licensure review in the US: the three-dose 
vaccine rLP2086 (Trumenba®, Pfizer) and the two-dose vaccine 4CMenB (Bexsero®, 
Novartis Vaccines and Diagnostics, Siena, Italy). Because 4CMenB had already been 
licensed in Europe and Australia in 2013 whereas rLP2086 was not yet licensed in any 
country, we thought 4CMenB would be more acceptable in the target population. The 
Centers for Disease Control and Prevention (CDC) therefore submitted an expanded access 
Investigational New Drug (IND) application to the Food and Drug Administration (FDA) to 
allow use of 4CMenB to control the outbreak at University A. The CDC, New Jersey 
Department of Health (NJDOH), Princeton Health Department, and University A 
collaborated to provide the two-dose vaccination series to the population at risk in the 
outbreak beginning in December 2013.
Here, we describe the epidemiologic investigation of the outbreak that led to the decision to 
vaccinate and the implementation of the vaccination campaign with investigational 4CMenB 
vaccine.
Patients and Methods
Case investigation
Meningococcal disease is nationally notifiable and suspected cases are reported directly to 
state or local public health authorities. The current Advisory Committee on Immunization 
Practices guidelines define an organization-based meningococcal disease outbreak as the 
occurrence of 3 or more cases in 3 months in persons with a common organizational 
affiliation but without direct close contact and a resulting attack rate of greater than 10 per 
100,000 [1]. An outbreak case was defined as a case of serogroup B meningococcal disease 
with laboratory results consistent with the outbreak strain that occurred in a University A 
student or close contact of University A students. Cases were reported in New Jersey, Texas, 
Massachusetts, and Pennsylvania in the US as well as in Greece and were investigated by 
university and local and state health department staff to identify close contacts for antibiotic 
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chemoprophylaxis. The case-patient who became ill in Greece had been traveling with a 
group of University A students in Europe for three weeks prior to illness onset; no air travel 
contacts of this patient required chemoprophylaxis. NJDOH compiled data on all outbreak 
cases, including those initially reported elsewhere.
Molecular characterization
For eight cases, N. meningitidis serogroup was determined by slide agglutination at the state 
public health laboratory and confirmed by real-time polymerase chain reaction (rt-PCR) at 
CDC [2–4]. Serogroup determination and PorA typing for one case was performed in 
Greece using PCR.
At CDC, isolates were characterized using pulsed-field gel electrophoresis (PFGE), 
multilocus sequence typing (MLST), and molecular typing of fHbp, NhbA, NadA, and PorA 
as previously described [5–8]. Novartis assessed whether 4CMenB vaccine was expected to 
protect against the outbreak strain using human serum bactericidal assay (hSBA) and 
meningococcal antigen typing system (MATS) [9,10].
Epidemiologic investigation
Following the 6th outbreak case in October 2013, NJDOH invited CDC to assist with an on-
site investigation to determine the target population for potential vaccination. To understand 
whether cases shared epidemiologic links, case information gathered by NJDOH, the 
Princeton Health Department, and University A was compiled and reviewed. The population 
at risk [1] was characterized through interviews with University A staff and students and 
review of university data on student ages, living arrangements, and social interactions.
Vaccination clinic
In November 2013, use of 4CMenB vaccine was authorized per FDA under the expanded 
access IND regulations (21 CFR 312.320). The primary goal of the expanded access IND 
was to make vaccine available to the population at risk for serogroup B meningococcal 
disease during the outbreak given the lack of an adequate, approved alternative for 
prevention of this potentially life-threatening condition in the US. The primary purpose of 
an expanded access IND is to provide access to a vaccine or treatment; it is not intended to 
establish safety and efficacy of the product.
CDC’s Institutional Review Board (IRB) served as the IRB for this IND protocol; the 
university’s IRB deferred to CDC. Written informed consent was obtained from all vaccine 
recipients and parental consent and written assent were obtained for recipients under age 18 
years.
University A and CDC collaborated to provide students, parents, faculty, and staff with 
accurate and timely information about the 4CMenB vaccination program; implement the 
vaccination campaign; and monitor adverse events following vaccination. Potential vaccine 
recipients were notified of the clinic through multiple mechanisms, including email, posters, 
and text messages. At the clinic, precautions and contraindications for vaccination were 
assessed through a screening questionnaire for each recipient; those with questions about the 
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vaccine or medical conditions received further evaluation from a clinical team composed of 
medical doctors from CDC and University A. Vaccination coverage was monitored through 
real-time entry of vaccination into recipients’ electronic health records or, for non-students, 
by collecting copies of the informed consent paperwork. Reports of adverse events 
following vaccination are being collected passively via phone and student health clinic visits 
and actively via surveys administered at the time of second dose administration and 30 days 
after receipt of the second dose.
Results
Case ascertainment
Between March and November 2013, seven cases occurred in University A undergraduates 
and one additional case occurred in a high school student who became ill after staying in an 
undergraduate dormitory at University A. Excluding the one case that occurred during the 
university’s summer break, case-patients lived or stayed in 6 out of the 50 undergraduate 
dormitories at University A immediately prior to disease onset. No cases occurred in 
graduate students, faculty, staff, local community members, or family members of case-
patients. The median time between cases was 26 days (range 12–94).
All 8 of these case-patients experienced headache and fever and 7 of the 8 developed a rash. 
Seven case-patients had meningitis while one had bloodstream infection only. All case-
patients were hospitalized; the median length of stay was 7 days (range 5–10 days). None of 
these 8 cases was fatal, but three case-patients had long-term sequelae (unilateral hearing 
loss (n=1), neurocognitive deficits (n=1), and chronic headaches (n=1)).
The 9th case occurred in March 2014, after the 4CMenB vaccination campaigns and 109 
days after the 8th case. This case occurred in a student at a different university who had close 
contact with University A undergraduates at an off-campus social event 8 days prior to 
disease onset. The 9th case-patient exhibited a petechial rash but did not have evidence of 
meningitis. The ninth case was fatal, bringing the overall outbreak case-fatality ratio to 11%.
Outbreak case-patient ages ranged from 17 to 21 years (median 19); cases occurred in both 
males (56%) and females and across four undergraduate classes (Figure 1). No case-patients 
had a prior diagnosis of a medical condition that increases risk of meningococcal disease 
(i.e., functional or anatomic asplenia or persistent complement component deficiency) [1]. 
The annualized attack rate of serogroup B meningococcal disease among University A 
undergraduates was 134 per 100,000.
Immediately upon identification of each case, close contacts of case-patients were identified 
by University A, NJDOH, the Princeton Health Department, and other state and local health 
departments and were recommended antibiotic chemoprophylaxis. Close contacts include 
household contacts (including roommates), child care center contacts, and anyone else with 
a direct exposure to a case-patient’s oral secretions [1]. No secondary cases occurred in 
close contacts of case-patients. In addition to chemoprophylaxis for close contacts, in May 
2013 the university issued recommendations for students to reduce sharing of eating and 
drinking materials and other activities that could result in contact with oral secretions.
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Molecular characterization
All cases were confirmed as serogroup B meningococcal disease and had the same PorA 
type (P1.5-1,2-2). Isolates from the eight cases identified in the US were characterized 
further; all were sequence type 409 (ST-409) of clonal complex 41/44/Lineage 3 and had the 
same PFGE pattern (429) and antigen types (fHbp 1.276, NhbA p0002, and NadA negative 
by Novartis nomenclature). The fHbp and NhbA antigens in the outbreak strain 
demonstrated cross-reactivity with 4CMenB vaccine antigens by MATS; hSBA testing 
showed that serum from people vaccinated with 4CMenB was able to kill the outbreak 
strain.
Epidemiologic investigation
The outbreak spanned two academic years. Only one person was identified as a close contact 
of more than one case (cases 4 and 7); however, these cases occurred nearly 6 months apart 
and the contact in question received chemoprophylaxis immediately following the 
identification of each case. No case-patients were found to share common extracurricular 
activities and no cases occurred in the same dormitory within an academic year.
In the 2013–2014 academic year, 5,241 undergraduate and 2,666 graduate students were 
enrolled at University A. More than 98% of undergraduates and 20% of graduate students 
lived in on-campus dormitories. For undergraduates, the mean age was 21 years (range 16–
31) and vaccination coverage with quadrivalent meningococcal conjugate vaccine 
(MenACWY) was >99.9%. Graduate students living in the graduate student dormitory were 
significantly younger than graduate students living in university-owned apartments, with 
mean ages of 24.1 and 26.4 years, respectively (t-test, t=13, p<0.0001). Social mixing 
between undergraduate and graduate students was reported to be uncommon but extant; 
however, the degree of social mixing could not be quantified.
Based on this investigation, the target population for vaccination included: University A 
undergraduate students (n = 5,241), graduate students living in undergraduate and graduate 
student dormitories (n = 541), graduate students, faculty, and staff with a medical condition 
that increases risk of meningococcal disease (n = 11), and spouses and care-givers of 
undergraduate and graduate students living in a dormitory with the students (n = 6).
Vaccination Campaign
The first-dose vaccination clinic was held December 9–12, 2013 and the second-dose clinic 
was held February 17–20, 2014. Additional small clinics were held for persons unable to 
attend the larger clinics. Through May 14, 2014, 94.9% of the target population had received 
at least 1 dose of the vaccine and 89.1% had received both doses (Table 1). Within this 
target population, coverage was highest among undergraduate students, of whom 96.6% 
received the first dose and 91.4% received both doses (Table 1). As of February 1, 2015, one 
serious adverse event was deemed possibly related to the vaccine (a case of rhabdomyolysis 
with onset 1 day after the second dose), but no concerning patterns of adverse events 
following vaccination have been observed. Monitoring for adverse events is ongoing.
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Through February 1, 2015, no cases of serogroup B meningococcal disease have been 
reported in individuals who received the 4CMenB vaccine. However, as noted above, the 9th 
case did occur after the vaccination campaigns. The 9th case-patient was a student at another 
university who had close contact with several University A students, most of whom had 
received 2 doses of 4CMenB, prior to disease onset. The student body of the second 
university was not considered to be at increased risk for meningococcal disease due to this 
incident.
Discussion
In this report, we describe the first time an expanded access IND program for an 
investigational vaccine has been implemented in response to a serogroup B meningococcal 
disease outbreak in the US. The attack rate among undergraduate students at University A, 
134 per 100,000, was more than 1,400 times greater than the national incidence in this age 
group [1, CDC unpublished data]. Prior to routine MenACWY vaccination, most 
meningococcal disease outbreaks on college campuses were caused by serogroup C [11,12]. 
However, serogroup C outbreaks have declined with high MenACWY coverage in 
adolescents [13], leaving serogroup B as the cause of recent meningococcal outbreaks on 
college campuses.
The sequence type of the bacterial strain isolated in this outbreak, ST-409, is uncommon in 
the US. Aside from the samples received from this outbreak, CDC has received only 9 
(0.25%) serogroup B ST-409 isolates out of 3,595 unique case isolates that have been 
characterized by MLST (isolates collected 1911–2014). None of these other ST-409 isolates 
had the same antigen profile as the University A outbreak strain. To our knowledge, no other 
outbreaks associated with ST-409 have been reported in the US or elsewhere. Little is 
known about the clinical presentation of meningococcal disease caused by ST-409, but in 
this outbreak the case-fatality ratio and proportion of case-patients with meningitis were 
consistent with those from meningococcal disease surveillance data for the US [14].
It is not clear why this strain caused an outbreak at University A. This strain might be more 
invasive than other N. meningitidis sequence types and indeed it is part of the ST-41/44 
clonal complex, which is thought to be hypervirulent [15]. Alternatively, the undergraduate 
population may have had low baseline immunity to this novel bacterial strain, leading to a 
high attack rate once it was introduced into the student population.
Defining the population at risk in meningococcal disease outbreaks can be challenging. In 
this outbreak, cases occurred in students of four undergraduate class years, and therefore the 
entire undergraduate population was targeted for vaccination. While no cases occurred in 
graduate students, graduate students living in on-campus dormitories were targeted for 
vaccination because the increased risk of meningococcal disease for college freshmen living 
in dormitories [16–19] raised concerns that dormitory living might also increase risk for 
other populations. Furthermore, most outbreak-associated cases of meningococcal disease in 
the US occur in persons aged <25 years and the mean age of the graduate students living in 
dormitories was <25 years [11, CDC unpublished data]. While the population at risk must be 
determined separately for each outbreak of meningococcal disease, we hope the process 
McNamara et al. Page 7
Pediatrics. Author manuscript; available in PMC 2016 May 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
used to define the population at risk at University A can inform this determination in future 
outbreaks.
Over 5,000 students received 4CMenB vaccine during the 4-day first-dose vaccination 
campaign. Several factors likely contributed to the campaign’s success. First, the university 
provided information about meningitis and the vaccination clinics to students and parents 
through multiple mechanisms, including emails, posters, text messages, a student-created 
video, and town hall meetings featuring University A and CDC staff. In addition, efficient 
clinic management and short wait times for participants resulted in high throughput. Finally, 
the high attack rate of meningococcal disease and the occurrence of cases shortly before the 
vaccination campaign likely motivated students to receive the vaccine. This highly 
successful vaccination campaign provides a model for future vaccination campaigns in 
response to outbreaks on college campuses.
As of February 1, 2015, no additional serogroup B meningococcal disease cases occurred at 
University A. While two doses of the vaccine are critical for a sustained immune response 
[20], one study demonstrated that adolescents also have a strong initial immune response 
after a single dose [21]. This fact might have contributed to the absence of cases between the 
first and second vaccination campaigns. However, a case did occur in a close contact of 
University A students in March 2014. Most of the students with whom the last case-patient 
had contact had received two doses of 4CMenB vaccine. The occurrence of this case 
demonstrates that the vaccination campaign had not eliminated carriage from the University 
A population by this time and that transmission of the outbreak strain was ongoing. This 
finding is consistent with a recent study demonstrating that 4CMenB has at most a modest 
impact on prevalence of meningococcal carriage in vaccinated people [22]. Ultimately, it is 
unknown whether additional cases would have occurred in University A students in the 
absence of the vaccination campaign, but the lack of cases in vaccinated persons combined 
with the evidence of ongoing transmission in the population suggests the campaign did 
succeed in providing primary protection to the student population.
The first vaccine for serogroup B meningococcal disease, rLP2086 (Trumenba®, Pfizer) 
was licensed for use in individuals 10–25 years old on October 29, 2014, and 4CMenB was 
approved for use in the same age group on January 23, 2015. Although the Advisory 
Committee on Immunization Practices has not yet developed recommendations for the use 
of either vaccine, CDC formed a meningitis outbreak working group to provide interim 
guidance for responding to outbreaks of serogroup B meningococcal disease. These 
guidelines are available online at http://www.cdc.gov/meningococcal/outbreaks/vaccine-
serogroupb.html. While the number of sporadic cases of serogroup B meningococcal disease 
occurring in adolescents each year is at historic lows, the potential impact of MenB vaccines 
on both sporadic disease and outbreaks will be important to consider in the development of 
recommendations for use of licensed MenB vaccines in the US.
Conclusions
No serogroup B meningococcal disease cases occurred in students who had received 1 or 
more doses of 4CMenB vaccine, suggesting 4CMenB was effective in protecting vaccinated 
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individuals from disease. However, the 9th case demonstrates that carriage of serogroup B 
Nesisseria meningitidis among vaccinated persons was not eliminated. The outbreak 
investigation and highly successful vaccination campaign described here can serve as a 
model for how to approach similar outbreaks in the future.
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What’s Known on This Subject
Outbreaks of serogroup B meningococcal disease occur at universities and other 
organizations. However, until October 2014 options for control of serogroup B outbreaks 
were limited by the absence of a licensed vaccine for serogroup B meningococcal disease 
in the US.
What This Study Adds
This report describes a serogroup B outbreak at a university in 2013 and the campaign 
with investigational serogroup B vaccine held in response. This was the first use of a 
serogroup B vaccine as an outbreak response in the US.
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Figure 1. 
Timeline of outbreak cases and response activities.
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